These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21270522)

  • 1. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
    Donia M; Maksimovic-Ivanic D; Mijatovic S; Mojic M; Miljkovic D; Timotijevic G; Fagone P; Caponnetto S; Al-Abed Y; McCubrey J; Stosic-Grujicic S; Nicoletti F
    Cell Cycle; 2011 Feb; 10(3):492-9. PubMed ID: 21270522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
    Rothweiler F; Michaelis M; Brauer P; Otte J; Weber K; Fehse B; Doerr HW; Wiese M; Kreuter J; Al-Abed Y; Nicoletti F; Cinatl J
    Neoplasia; 2010 Dec; 12(12):1023-30. PubMed ID: 21170266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.
    Mijatovic S; Maksimovic-Ivanic D; Mojic M; Timotijevic G; Miljkovic D; Mangano K; Donia M; Di Cataldo A; Al-Abed Y; Cheng KF; Stosic-Grujicic S; Nicoletti F
    J Cell Physiol; 2011 Jul; 226(7):1803-12. PubMed ID: 21506111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.
    Donia M; Mangano K; Fagone P; De Pasquale R; Dinotta F; Coco M; Padron J; Al-Abed Y; Giovanni Lombardo GA; Maksimovic-Ivanic D; Mijatovic S; Zocca MB; Perciavalle V; Stosic-Grujicic S; Nicoletti F
    Oncol Rep; 2012 Aug; 28(2):682-8. PubMed ID: 22665020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.
    Maksimovic-Ivanic D; Mijatovic S; Miljkovic D; Harhaji-Trajkovic L; Timotijevic G; Mojic M; Dabideen D; Cheng KF; McCubrey JA; Mangano K; Al-Abed Y; Libra M; Garotta G; Stosic-Grujicic S; Nicoletti F
    Mol Cancer Ther; 2009 May; 8(5):1169-78. PubMed ID: 19417156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
    Mojic M; Mijatovic S; Maksimovic-Ivanic D; Dinic S; Grdovic N; Miljkovic D; Stosic-Grujicic S; Tumino S; Fagone P; Mangano K; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
    Cell Cycle; 2012 Mar; 11(6):1174-82. PubMed ID: 22370480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
    Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
    Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
    Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
    Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
    Mojic M; Mijatovic S; Maksimovic-Ivanic D; Miljkovic D; Stosic-Grujicic S; Stankovic M; Mangano K; Travali S; Donia M; Fagone P; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
    Mol Pharmacol; 2012 Oct; 82(4):700-10. PubMed ID: 22798453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells.
    Pereira M; Vale N
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
    Maksimovic-Ivanic D; Mojic M; Bulatovic M; Radojkovic M; Kuzmanovic M; Ristic S; Stosic-Grujicic S; Miljkovic D; Cavalli E; Libra M; Fagone P; McCubrey J; Nicoletti F; Mijatovic S
    Leuk Res; 2015 Oct; 39(10):1088-95. PubMed ID: 26220866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saquinavir-NO inhibits IL-6 production in macrophages.
    Momčilović M; Mangano K; Jevtić B; Mammana S; Stošić-Grujičić S; Nicoletti F; Miljković D
    Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):499-506. PubMed ID: 24842127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
    Shankar S; Chen X; Srivastava RK
    Prostate; 2005 Feb; 62(2):165-86. PubMed ID: 15389801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
    Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
    In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
    Chavanet P; Piroth L; Grappin M; Buisson M; Gourdon F; Cabié A; Duong M; Brunel-Dalmas F; Peytavin G; Portier H
    HIV Clin Trials; 2001; 2(5):408-12. PubMed ID: 11673815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.
    Huerta-Yepez S; Baritaki S; Baay-Guzman G; Hernandez-Luna MA; Hernandez-Cueto A; Vega MI; Bonavida B
    Nitric Oxide; 2013 Feb; 29():17-24. PubMed ID: 23246440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
    Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
    Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.